Stroke
Conference Coverage
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a...
Conference Coverage
ASCEND: Aspirin shows hint of dementia protection in T2D
Conference Coverage
PRAGUE-17: LAA closure holds up against DOACs out to 4 years
Most outcomes remained unchanged, but follow-up imaging curtailed by the COVID-19 pandemic leaves an unfortunate gap with regard to late device-...
Conference Coverage
Vegetable fats tied to lower stroke risk, animal fats to higher risk
Higher intake of vegetable fats, such as olive oil and nuts, was associated with a lower risk for stroke, and animal fats, especially processed...
Conference Coverage
Stroke thrombectomy alone fails noninferiority to bridging tPA
The rate of good functional outcome was 57% for patients who underwent direct thrombectomy and 65% among patients who received IV thrombolysis...
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...
Conference Coverage
Estimating insulin resistance may help predict stroke, death in T2D
The estimated glucose disposal rate may be useful way to determine first stroke risk in type 2 diabetes.
From the Journals
Is AFib a stroke cause or innocent bystander? The debate continues
Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.
Conference Coverage
Sexual assault in women tied to increased stroke, dementia risk
“A history of sexual assault was particularly related to white matter hyperintensities in the parietal lobe, [which] have been linked to Alzheimer...
Conference Coverage
Aspirin and heparin increase bleeding risk during EVT
New data show that aspirin and heparin, alone or in combination, double the risk for symptomatic intracranial hemorrhage when given during...
Conference Coverage
Tranexamic acid fails to prevent ICH growth: TRAIGE trial results
“Larger studies with more specified population are needed to further assess safety and efficacy of tranexamic acid in patients with ICH.”